Table 1 General characteristics of study patients (n = 431)
From: Potential drug-drug interactions among pneumonia patients: do these matter in clinical perspectives?
Characteristic | Patients: n (%a) |
|---|---|
Gender | |
 Male | 220 (51) |
 Female | 211 (49) |
Age (years) | |
 ≤40 | 63 (14.6) |
 41–60 | 176 (40.8) |
 >60 | 192 (44.5) |
 Median (IQR) | 60 (50–70) |
Drugs prescribed per patient | |
 ≤5 | 42 (9.7) |
 6–10 | 165 (38.3) |
 >10 | 224 (52) |
 Median (IQR) | 11 (8–14) |
Hospital stay (days) | |
 ≤2 | 79 (18.3) |
 3–4 | 143 (33.2) |
 >4 | 209 (48.5) |
 Median (IQR) | 4 (3–6) |
Number of comorbidities | |
 No comorbidities | 24 (5.6) |
 1–2 | 170 (39.4) |
 3–4 | 127 (29.4) |
 5 | 10 (2.3) |
Comorbidities | |
 Hypertension | 220 (51) |
 Diabetes mellitus | 120 (27.8) |
 Stroke | 120 (27.8) |
 Chronic obstructive pulmonary disease | 37 (8.6) |
 Ischemic heart disease | 36 (8.3) |
 Urinary tract infection | 34 (7.9) |
 Tuberculosis | 25 (5.8) |
 Hepatitis | 24 (5.6) |
 Chronic kidney disease | 20 (4.6) |
 Asthma | 16 (3.7) |
 Congestive cardiac failure | 14 (3.2) |
 Post tuberculosis bronchiectasis | 12 (2.8) |
 Malaria | 10 (2.3) |
 Decompensated chronic liver disease | 10 (2.3) |
 Left ventricular failure | 9 (2.1) |
 Miscellaneous | 167 (38.7) |